Author Topic: (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT  (Read 97 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
74 Views
Last post April 17, 2019, 02:42:04 pm
by agate
1 Replies
89 Views
Last post May 29, 2020, 09:45:07 pm
by agate
0 Replies
25 Views
Last post March 22, 2020, 02:55:01 pm
by agate
0 Replies
15 Views
Last post June 18, 2023, 08:59:26 am
by agate
1 Replies
5 Views
Last post March 27, 2024, 02:58:23 pm
by agate